Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
المؤلفون المشاركون
Zheng, Mao-hua
Sun, Hong-tao
Xu, Ji-guang
Yang, Gang
Huo, Lei-ming
Zhang, Pan
Tian, Jin-hui
Yang, Ke-hu
المصدر
العدد
المجلد 2016، العدد 2016 (31 ديسمبر/كانون الأول 2016)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2016-02-24
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background.
To comprehensively assess the efficacy and safety of whole-brain radiotherapy (WBRT) combined with gefitinib/erlotinib for treatment of brain metastases (BM) from non-small-cell lung cancer (NSCLC).
Methods.
Databases including PubMed, EMBASE.com, Web of Science, and Cochrane Library were searched from inception to April 12, 2015.
Studies on randomized controlled trials (RCTs) and case-control trials comparing WBRT combined with gefitinib/erlotinib versus WBRT alone for BM from NSCLC were included.
Literature selection, data extraction, and quality assessment were performed independently by two trained reviewers.
RevMan 5.3 software was used to analyze data.
Results.
A total of 7 trials involving 622 patients were included.
Compared with WBRT alone or WBRT plus chemotherapy, WBRT plus gefitinib/erlotinib could significantly improve response rate (OR = 2.16, 95% CI: 1.35–3.47; P = 0.001 ), remission rate of central nervous system (OR = 6.06, 95% CI: 2.57–14.29; P < 0.0001 ), disease control rate (OR = 3.34, 95% CI: 1.84–6.07; P < 0.0001 ), overall survival (HR = 0.72, 95% CI: 0.58–0.89; P = 0.002 ), and 1-year survival rate (OR = 2.43, 95% CI: 1.51–3.91; P = 0.0002 ).
In adverse events (III-IV), statistically significant differences were not found, except for rash (OR = 7.96, 95% CI: 2.02–31.34; P = 0.003 ) and myelosuppression (OR = 0.19, 95% CI: 0.07–0.51; P = 0.0010 ).
Conclusions.
WBRT plus gefitinib/erlotinib was superior to WBRT alone and well tolerated in patients with BM from NSCLC.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Zheng, Mao-hua& Sun, Hong-tao& Xu, Ji-guang& Yang, Gang& Huo, Lei-ming& Zhang, Pan…[et al.]. 2016. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Zheng, Mao-hua…[et al.]. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Zheng, Mao-hua& Sun, Hong-tao& Xu, Ji-guang& Yang, Gang& Huo, Lei-ming& Zhang, Pan…[et al.]. Combining Whole-Brain Radiotherapy with GefitinibErlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis. BioMed Research International. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1098221
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1098221
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر